| HOME >> MEDICINE >> TECHNOLOGY |
Society of Nuclear Medicine Abstracts
Cytogen also reported today the presentation of a number of abstracts related to investigator-sponsored studies with QUADRAMET or Cytogen's monoclonal antibody-based molecular imaging agent for prostate cancer, PROSTASCINT(R) (capromab pendetide), at the 54th Annual Meeting of the Society of Nuclear Medicine taking place through June 6, 2007 in Washington, DC. The abstract titles and publication numbers are as follows:
"Combination of radionuclide therapy using Sm-153-Lexidronam and chemotherapy in patients with bone metastases of hormone refractory prostate cancer (HRPC): First results", by Nestle, et al. Saarland University Medical Center, Homburg/Saar, Germany (Abstract No. 127, Sunday, June 3, 2007, 5:03 PM)
"Radiation safety of outpatient therapy in patients receiving high-dose Sm-153 EDTMP treatment: A prospective study", by Bartosh et al., The University of Texas MD Anderson Cancer Center, Houston, Texas (Abstract No. 2027, Monday June 4, 2007, 1:42 PM)
"Comparison of animal biodistribution of EDTMP labeled with various beta emitting lanthanides", by Sohaib, et al., Pakistan Institute of Nuclear Sciences and Technology (PINSTECH), Islamabad, Pakistan (Abstract No. 461, Tuesday June 5, 2007, 3:18 PM)
"ProstaScint imaging - Reviewing the fundamentals", by Sureshbabu, et al., Excel Diagnostics Imaging Clinics, Houston, Texas (Abstract No. 2103, Monday June 4, 2007, 2:30 PM)
"Use of SPECT/CT in tumor localization: SPECT/CT versus planar and SPECT imaging in tumor localization" by Levi, et al. Florida Hospital College of Health Sciences, Orlando, Florida (Abstract No. 2228, Monday, June 4, 2007, 8:50 AM)
"Added value of SPECT-CT in patients explored by 111In-Capromab Pendetide (ProstaScint)", by Belhocine, et al. (Abstract No. 653, Wednesday June 6, 2007, 9:45 AM)
'"/>